This brand name is authorized in Austria, Brazil, Estonia, Finland, Spain.
The drug FARLUTAL contains one active pharmaceutical ingredient (API):
1
|
UNII
C2QI4IOI2G - MEDROXYPROGESTERONE ACETATE
|
|
Medroxyprogesterone acetate exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L02AB02 | Medroxyprogesterone | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AB Progestogens |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 522236201118418, 522236202114416 |
| EE | Ravimiamet | 1013195 |
| ES | Centro de información online de medicamentos de la AEMPS | 57258 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 161794 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.